140 related articles for article (PubMed ID: 36160743)
1. Adjuvant chemoradiotherapy
Kang WZ; Shi JM; Wang BZ; Xiong JP; Shao XX; Hu HT; Jin J; Tian YT
World J Gastrointest Oncol; 2022 Aug; 14(8):1540-1551. PubMed ID: 36160743
[TBL] [Abstract][Full Text] [Related]
2. Comparison of preoperative concurrent chemoradiotherapy with chemotherapy alone in patients with locally advanced siewert II and III adenocarcinoma of the esophagogastric junction.
Ge X; Zhao Q; Song Y; Li J; Liu M; Bai W; Qiao X
Eur J Surg Oncol; 2018 Apr; 44(4):502-508. PubMed ID: 29395438
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection.
Shi J; Kang W; Tang Y; Li N; Jiang L; Yang L; Wang S; Song Y; Liu Y; Fang H; Lu N; Qi S; Chen B; Li Y; Tian Y; Jin J
Front Oncol; 2022; 12():916937. PubMed ID: 35903692
[TBL] [Abstract][Full Text] [Related]
4. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
5. Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG).
Shen J; Zhu X; Du Y; Zhu Y; Yu P; Yang L; Xu Z; Huang L; Zhang Y; Zhang Y; Liu L; Cheng X
Trials; 2021 Oct; 22(1):753. PubMed ID: 34717717
[TBL] [Abstract][Full Text] [Related]
6. Impact of the Siewert Classification on the Outcome of Patients Treated by Preoperative Chemoradiotherapy for a Nonmetastatic Adenocarcinoma of the Oesophagogastric Junction.
Moureau-Zabotto L; Teissier E; Cowen D; Azria D; Ellis S; Resbeut M
Gastroenterol Res Pract; 2015; 2015():404203. PubMed ID: 26448741
[TBL] [Abstract][Full Text] [Related]
7. Identification of patients with lymph node metastasis from gastric cancer who may benefit from adjuvant chemoradiotherapy after D2 dissection--do N3 patients benefit from additional radiation?
Fan M; Li G; Shen L; Zhang H; Liang L; Zhang Z
Br J Radiol; 2016; 89(1059):20150758. PubMed ID: 26728420
[TBL] [Abstract][Full Text] [Related]
8. Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction.
Li G; Zhang Z; Ma X; Zhu J; Cai G
PLoS One; 2013; 8(1):e54233. PubMed ID: 23372688
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathologic characteristics and prognostic factors of gastroesophageal junction tumors according to Siewert classification.
Ustaalioğlu BBÖ; Tilki M; Sürmelioğlu A; Bilici A; Gönen C; Ustaalioğlu R; Balvan Ö; Aliustaoğlu M
Turk J Surg; 2017; 33(1):18-24. PubMed ID: 28589183
[TBL] [Abstract][Full Text] [Related]
10. Identification of Patients With Locally Advanced Gastric Cancer Who May Benefit From Adjuvant Chemoradiotherapy After D2 dissection: A Propensity Score Matching Analysis.
Wang SB; Qi WX; Chen JY; Xu C; Cao WG; Cai R; Cao L; Cai G
Front Oncol; 2021; 11():648978. PubMed ID: 33869049
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemoradiation versus chemotherapy for stage III gastric cancer after surgery with curative intent.
Turanli S; Atalay C; Berberoglu U; Gulben K
J Cancer Res Ther; 2015; 11(2):369-74. PubMed ID: 26148602
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Efficacy of Neoadjuvant Concurrent Chemoradiotherapy for Potentially Resectable Advanced Siewert Type II and III Adenocarcinomas of the Esophagogastric Junction.
Tian Y; Wang J; Qiao X; Zhang J; Li Y; Fan L; Zhang Z; Zhao X; Tan B; Wang D; Yang P; Zhao Q
Front Oncol; 2021; 11():756440. PubMed ID: 34858829
[TBL] [Abstract][Full Text] [Related]
13. Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma.
Kim YS; Hwang IG; Park SE; Go SI; Kang JH; Park I; Oh SY; Ji JH; Song HN; Park SH; Kim ST; Park JO
Cancer Chemother Pharmacol; 2016 May; 77(5):979-85. PubMed ID: 27017615
[TBL] [Abstract][Full Text] [Related]
14. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial.
Stahl M; Walz MK; Riera-Knorrenschild J; Stuschke M; Sandermann A; Bitzer M; Wilke H; Budach W
Eur J Cancer; 2017 Aug; 81():183-190. PubMed ID: 28628843
[TBL] [Abstract][Full Text] [Related]
15. [Effect of splenic hilar lymphadenectomy on locally advanced Siewert type Ⅱ and Ⅲ adenocarcinoma of esophagogastric junction with a tumor diameter ≥4 cm: a five-year survival analysis].
Lin JX; Wu D; Jiang YM; Chen JY; Lin GT; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Zheng CH; Huang CM
Zhonghua Wai Ke Za Zhi; 2022 Sep; 60(9):853-859. PubMed ID: 36058712
[No Abstract] [Full Text] [Related]
16. Survival outcomes and patterns of failure after D2 dissection and adjuvant chemoradiotherapy for locally advanced gastric cancer: a retrospective study.
Yang W; Hu R; Li GC; Zhou ML; Wang Y; Shen LJ; Liang LP; Zhang Z
Br J Radiol; 2018 Sep; 91(1089):20170594. PubMed ID: 29927628
[TBL] [Abstract][Full Text] [Related]
17. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
18. Long-term oncological outcomes of laparoscopic versus open transhiatal resection for patients with Siewert type II adenocarcinoma of the esophagogastric junction.
Sugita S; Kinoshita T; Kuwata T; Tokunaga M; Kaito A; Watanabe M; Tonouchi A; Sato R; Nagino M
Surg Endosc; 2021 Jan; 35(1):340-348. PubMed ID: 32025923
[TBL] [Abstract][Full Text] [Related]
19. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.
Sclafani F; Brown G; Cunningham D; Wotherspoon A; Tait D; Peckitt C; Evans J; Yu S; Sena Teixeira Mendes L; Tabernero J; Glimelius B; Cervantes A; Thomas J; Begum R; Oates J; Chau I
Ann Oncol; 2016 Aug; 27(8):1557-65. PubMed ID: 27217542
[TBL] [Abstract][Full Text] [Related]
20. Comparison of neoadjuvant regimens for resectable gastroesophageal junction cancer: a systematic review of randomized clinical trials across three decades.
Nishikawa G; Banik P; Thawani R; Kardosh A; Wood SG; Nabavizadeh N; Chen EY
J Gastrointest Oncol; 2022 Jun; 13(3):1454-1466. PubMed ID: 35837173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
